Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Giant Cell Temporal Arteritis Followed by Severe Encephalopathy Induced by Immunotherapy in a Patient with Metastatic Renal Cell Carcinoma Achieving Durable Partial Response: A Case Report

O. Fiala, M. Tkadlecová, K. Pivovarčíková, J. Baxa, P. Stránský, D. Šiková, M. Hora, J. Fínek

. 2024 ; 17 (1) : 921-927. [pub] 20240826

Status not-indexed Language English Country Switzerland

Document type Case Reports, Journal Article

Persistent link   https://www.medvik.cz/link/bmc25002487

INTRODUCTION: Combined immuno-oncology (IO) regimens are the cornerstone of the current front-line systemic therapy for metastatic renal cell carcinoma (mRCC). Despite the fact that combined IO regimens show high efficacy, they are often accompanied by a wide spectrum of immune-related adverse effects (irAEs). CASE PRESENTATION: We describe a case of rare irAEs manifested as giant cell temporal arteritis (GCA) followed by severe encephalopathy occurring after continuing immunotherapy in a 66-year-old man with mRCC receiving a combination of ipilimumab and nivolumab in the first line of systemic therapy. GCA occurred 4 months after the initiation of IO and responded promptly to the low-dose prednisone therapy. Four months after the continuation of nivolumab maintenance, the patient was hospitalized due to severe irAE encephalopathy which presented as psycho-behavioral abnormalities and progressive cognitive decline. He was treated with high-dose methylprednisolone which led to complete resolution of the symptoms and IO was permanently discontinued. The patient achieved a durable partial response. CONCLUSION: Both GCA and the subsequent encephalopathy in our patient responded well to the corticosteroid therapy, leading to the complete resolution of the symptoms and the patient achieved a durable partial response. Although the risk of severe neurologic irAEs affecting the central nervous system induced by IO re-administration, following previous discontinuation due to irAE, is not well-defined because of their rarity, this case highlights the need for caution, particularly in cases with a history of previous irAE-associated GCA.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25002487
003      
CZ-PrNML
005      
20250123101917.0
007      
ta
008      
250117s2024 sz f 000 0|eng||
009      
AR
024    7_
$a 10.1159/000540660 $2 doi
035    __
$a (PubMed)39474545
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Fiala, Ondřej $u Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
245    10
$a Giant Cell Temporal Arteritis Followed by Severe Encephalopathy Induced by Immunotherapy in a Patient with Metastatic Renal Cell Carcinoma Achieving Durable Partial Response: A Case Report / $c O. Fiala, M. Tkadlecová, K. Pivovarčíková, J. Baxa, P. Stránský, D. Šiková, M. Hora, J. Fínek
520    9_
$a INTRODUCTION: Combined immuno-oncology (IO) regimens are the cornerstone of the current front-line systemic therapy for metastatic renal cell carcinoma (mRCC). Despite the fact that combined IO regimens show high efficacy, they are often accompanied by a wide spectrum of immune-related adverse effects (irAEs). CASE PRESENTATION: We describe a case of rare irAEs manifested as giant cell temporal arteritis (GCA) followed by severe encephalopathy occurring after continuing immunotherapy in a 66-year-old man with mRCC receiving a combination of ipilimumab and nivolumab in the first line of systemic therapy. GCA occurred 4 months after the initiation of IO and responded promptly to the low-dose prednisone therapy. Four months after the continuation of nivolumab maintenance, the patient was hospitalized due to severe irAE encephalopathy which presented as psycho-behavioral abnormalities and progressive cognitive decline. He was treated with high-dose methylprednisolone which led to complete resolution of the symptoms and IO was permanently discontinued. The patient achieved a durable partial response. CONCLUSION: Both GCA and the subsequent encephalopathy in our patient responded well to the corticosteroid therapy, leading to the complete resolution of the symptoms and the patient achieved a durable partial response. Although the risk of severe neurologic irAEs affecting the central nervous system induced by IO re-administration, following previous discontinuation due to irAE, is not well-defined because of their rarity, this case highlights the need for caution, particularly in cases with a history of previous irAE-associated GCA.
590    __
$a NEINDEXOVÁNO
655    _2
$a kazuistiky $7 D002363
655    _2
$a časopisecké články $7 D016428
700    1_
$a Tkadlecová, Michaela $u Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Pivovarčíková, Kristýna $u Sikl's Department of Pathology, Faculty of Medicine, Charles University, Pilsen, Czech Republic $u Bioptic Laboratory Ltd., Pilsen, Czech Republic
700    1_
$a Baxa, Jan $u Department of Imaging Methods, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Stránský, Petr $u Department of Urology, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Šiková, Dominika $u Department of Urology, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Hora, Milan $u Department of Urology, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Fínek, Jindřich $u Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic
773    0_
$w MED00173224 $t Case reports in oncology $x 1662-6575 $g Roč. 17, č. 1 (2024), s. 921-927
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39474545 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250117 $b ABA008
991    __
$a 20250123101911 $b ABA008
999    __
$a ok $b bmc $g 2254603 $s 1238490
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 17 $c 1 $d 921-927 $e 20240826 $i 1662-6575 $m Case reports in oncology $n Case Rep Oncol $x MED00173224
LZP    __
$a Pubmed-20250117

Find record

Citation metrics

Archiving options